Logo St.Gallen Breast Cancer Conference

19th St.Gallen International Breast Cancer Conference 2025

Primary Therapy of Patients with Early Breast Cancer. Evidence, Controversies, Consensus

12 – 15 March 2025, Vienna / Austria

Logo 19th St. Gallen Breast Cancer Conference Vienna 2025
Logo St.Gallen Breast Cancer Conference

19th St.Gallen International
Breast Cancer Conference 2025

Primary Therapy of Patients with Early Breast Cancer. Evidence, Controversies, Consensus

12 – 15 March 2025, Vienna / Austria

Logo 19th St.Gallen Breast Cancer Conference 2025

Satellite Symposia & Meet the Expert Programme

Please find the programme of our industry partners below.
Kindly note that not all symposia will be available for virtual attendance or as webcasts after the conference.

Wednesday, 12 March | 11:30-12:30

Navigating complex treatment decisions for gBRCAm HER2-negative eBC

Faculty:

Andrew Tutt, UK
Javier Cortés, Spain

Thursday, 13 March | 08:00-08:45

Current and Future Treatment Strategies for Patients With ER+/HER2- Early Breast Cancer

Title/Topic Speakers
Opening: High versus low risk definition in ER+/HER2- early breast cancer Michael Gnant, Austria
Treatment landscape and future strategies for ER+/HER2- early breast cancer Giuseppe Curigliano, Italy
Discussion and Q & A Michael Gnant, Austria

Thursday, 13 March | 11:30-12:30

Shaping the future of treatment decision making using Multigene Assays (MGA): an expert round table discussion

Chair: Stephen Chia, Canada

Title/Topic Speakers
Intro and housekeeping rules Stephen Chia, Canada
Optimizing systemic treatment choices using the Oncotype DX Breast Recurrence Score® Result pre-operatively Paluch Shimon, Israel
Directing Neoadjuvant Chemotherapy (NAC) using the Oncotype DX Breast Recurrence Score® Result Stephen Chia, Canada
Excised Invasive Carcinoma vs Diagnostic Core Biopsy: What Can We Learn from PreDX? Henry Cain, UK
Patient Perspectives: A Round Table Discussion All
Questions and Answer All
Summary and Coclusions Stephen Chia, Canada

Thursday, 13 March | 17:45-18:45

Elevating Care: Identifying Patients with High-Risk HR+ HER2- EBC Who May Benefit From Treatment Intensification?

Time Tittle/Topic Speakers
17:45–17:50 Welcome & introduction Michael Gnant, Austria
17:50–18:05 Identifying patients with HR+ HER2- EBC at high risk of recurrence Michael Gnant, Austria
18:05–18:20 Implementing evidence in everyday clinical practice Sara Tolaney, US
18:20–18:35 Refining patient management to maximize adherence and persistence Nadia Harbeck, Germany
18:35–18:40 Q&A All
18:40–18:45 Closing remarks Michael Gnant, Austria

Friday 14 March | 08:00-08:45

Illuminating a Better Path Forward for HR+, HER2- MBC: Bridging the Science and Art of Medicine in Clinical Decision-Making (CME/EBAC/AAPA/NCPD/IPCE-accredited)

Faculty:
Komal Jhaveri, United States of America
Giuseppe Curigliano, Italy

7:45: Check In & Breakfast

8:00: Symposium
Welcome, Introduction, and Goal-Setting
Clinical Care Catalyst Sessions
– Individualizing the Selection of First-Line Therapy in HR+, HER2- MBC: Latest Evidence, Practicalities, and Case
– Making the Most of the Expanding Therapeutic Arsenal for Pretreated HR+, HER2- MBC: New Data, Clinical Implications, and Cases
Symposium Summary, Open Discussion Forum, and Audience Q&A

Friday 14 March | 11:30-12:30

Completing the Picture: ADCs in Early HER2+ Breast Cancer Care

Chair: Nadia Harbeck, Germany

Timings Title/Topic Speaker(s)
11:30–11:35 Welcome and introduction Nadia Harbeck, Germany
11:35–11:45 Laying the framework: ADCs in HER2+ metastatic breast cancer François-Clément Bidard, France
11:45–11:55 Addressing the puzzle: The unmet need in HER2+ early breast cancer Marc Thill, Germany
11:55–12:05 Fitting the pieces: Integrating ADCs in HER2+ early breast cancer Elisabetta Munzone, Italy
12:05–12:25 Panel discussion and Q&A All speakers and chair
12:25–12:30 Thank you and closing statements Nadia Harbeck, Germany

Friday 14 March |17:45-18:45

Redefining Risk of Recurrence: Latest advances with CDK4/6 inhibitors in HR+/HER2− early breast cancer

Chair: Michael Gnant, Austria

Topics Speaker(s)
Welcome and Introduction Michael Gnant (Austria)
Reviewing the Treatment Landscape for Adjuvant Therapy for Patients with HR+/HER2− Early Breast Cancer Michael Gnant (Austria)
Exploring Adjuvant CDK4/6i Data for Patients with Node-Positive Disease Giuseppe Curigliano (Italy)
Applying Recent Data for Treating Patients with High-Risk N0 Disease Nadia Harbeck (Germany)
Key Takeaways and Live Q&A Michael Gnant (Austria)

Meet the Expert

Mini sessions during coffee breaks at Booth 10:

Best Practice in SCOUT Radar Localization from Biopsy to Surgery
P. Schrenk, Austria

Radar-Guided Localisation in Targeted Axillary Dissection
Maria Luisa Gasparri, Switzerland

RADIOSO Milan Trial: Rationale for Adopting SCOUT at IEO of Milan
Andrea Polizzi, Italy

Sign up for Newsletter

Stay up to date with all things SGBCC by signing up to our newsletter!